NCT04881799View on ClinicalTrials.gov

Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Pediatric Obesity
Interventions
DRUG

Phentermine/Topiramate (Qsymia)

Maximum dose of 15 mg/92 mg orally once daily in the morning. The dose will be titrated to this level (described earlier).

DRUG

Placebo

Daily injection

Trial Locations (1)

55414

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER